Antibe Therapeutics (ATBPF) 0.0600 $ATBPF
Antibe Therapeutics Announces No Material Change
Business Wire - Wed Feb 04, 6:45PM CST
Antibe Therapeutics Inc. ("Antibe"
(TSXV:ATE, OTCQX:ATBPF), wishes to confirm that its management is not aware of any corporate development or undisclosed material change to the Company or its operations that would account for the recent increase in market activity. Antibe continues to collect and assess data from its recently suspended Phase I clinical trial and will report back to the scientific community and the market with further details on its data review and corporate strategy as appropriate.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Suspends Its Phase I Clinical Trial Due to Safety Concerns
Business Wire - Fri Jan 16, 6:45AM CST
Antibe Therapeutics Inc. (TSXV:ATE; OTCQX:ATBPF) today announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Announces Appointment of Canadian Rheumatologist J. Carter Thorne to Its Clinical Advisory Board
Business Wire - Thu Dec 18, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV:ATE; OTCQX:ATBPF) is pleased to announce the expansion of its Clinical Advisory Board with the appointment of Canadian rheumatologist J. Carter Thorne, MD, FRCP(C), FACP, Chief of the Division of Rheumatology and Director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Canada.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Announces Appointment of US-Based Investor Relations Consultant
Business Wire - Tue Dec 16, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV: ATE, OTCQX: ATBPF) today announced that they have, subject to approval by securities regulators, entered into an Investor Relations Consulting Agreement with Stonegate Capital Partners Inc. ("Stonegate" based in Dallas, Texas. Under the terms of the agreement Stonegate will receive a monthly fee of $4,000 for a minimum of 6 months and will be granted 24,000 options. Such options will vest quarterly starting on the date of the grant, will be exercisable at a price of $0.52, and will expire October 31, 2017.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Reports Q2 2015 Interim Financial and Operating Results
Business Wire - Fri Nov 28, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV: ATE) filed its financial and operating results today for its fiscal quarter ended September 30, 2014.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Provides Update on Its Acute Pain Drug ATB-352
Business Wire - Tue Nov 25, 6:30AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in the Company's pipeline, as described in the CEO Letter of April 2014. These studies have demonstrated that ATB-352 potently inhibits the production of pain-signalling chemicals (prostaglandins) in rats, but does not produce significant ulceration in the stomach or intestine, even at very high doses. In the same study, administration of the painkiller ketoprofen caused severe and extensive intestinal ulceration and bleeding.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Completes Single Ascending Dose Portion of ATB-346 Phase I Program
Business Wire - Mon Oct 06, 6:30AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV:ATE; OTCQX:ATBPF) is pleased to report that the pre-scheduled single ascending dose portion of its Phase I program has been completed and has reached its primary objectives of safety and tolerability of ATB-346, up to the maximum dose tested (1500 mg). The results of this portion of the Phase I program have met the corporation's expectations based on extensive pre-clinical studies, and support the continuation of the Phase I program into the multiple ascending dose and food-effect portions, both of which are underway and are expected to be completed by January 2015.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Reports on Results of AGM Voting
Business Wire - Fri Oct 03, 6:30AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV:ATE; OTCQX:ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the Corporation held on October 1, 2014.
ATE.VN: 0.080 (+0.005)
Merriman Capital Announces Sponsorship of Antibe Therapeutics Inc. on OTCQX
Thomson Reuters ONE - Mon Sep 15, 8:01AM CDT
SAN FRANCISCO - September 15, 2014 - Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it will serve as the Principal American Liaison (PAL) for Antibe Therapeutics Inc. (OTCQX: ATBPF) ("Antibe Therapeutics" as it begins trading on OTCQX(R). The OTC announced today that the Antibe Therapeutics is now trading on the OTC market's highest tier, the OTCQX.
Antibe Therapeutics Commences Trading on the US OTCQX Marketplace
Business Wire - Mon Sep 15, 6:30AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that, as of today, common shares of the Corporation began trading in the United States on the OTCQX exchange under the ticker symbol "ATBPF". Antibe's common shares will continue to trade on the TSX Venture Exchange under the symbol "ATE".
ATE.VN: 0.080 (+0.005)
OTC Markets Group Welcomes Antibe Therapeutics to OTCQX®
PR Newswire - Mon Sep 15, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Antibe Therapeutics Inc. (TSX-V: ATE; OTCQX: ATBPF), a human drug development company, has qualified to trade on OTCQX®, the best marketplace.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics' Founder Leads Study Identifying a Novel Mechanism for Treating Inflammatory Bowel Disease
Business Wire - Fri Sep 05, 6:30AM CDT
Antibe Therapeutics Inc.'s Founder and Chief Scientific Officer, Dr. John Wallace, is the senior author of an article published this week in the prestigious scientific journal Proceedings of the National Academy of Science USA describing research that may lead to a significant improvement in the treatment of Crohn's Disease and Ulcerative Colitis, collectively known as "inflammatory bowel disease" (IBD).
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Announces No Material Change
Business Wire - Wed Feb 04, 6:45PM CST
Antibe Therapeutics Inc. ("Antibe"
(TSXV:ATE, OTCQX:ATBPF), wishes to confirm that its management is not aware of any corporate development or undisclosed material change to the Company or its operations that would account for the recent increase in market activity. Antibe continues to collect and assess data from its recently suspended Phase I clinical trial and will report back to the scientific community and the market with further details on its data review and corporate strategy as appropriate. ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Suspends Its Phase I Clinical Trial Due to Safety Concerns
Business Wire - Fri Jan 16, 6:45AM CST
Antibe Therapeutics Inc. (TSXV:ATE; OTCQX:ATBPF) today announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Announces Appointment of Canadian Rheumatologist J. Carter Thorne to Its Clinical Advisory Board
Business Wire - Thu Dec 18, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV:ATE; OTCQX:ATBPF) is pleased to announce the expansion of its Clinical Advisory Board with the appointment of Canadian rheumatologist J. Carter Thorne, MD, FRCP(C), FACP, Chief of the Division of Rheumatology and Director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Canada. ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Announces Appointment of US-Based Investor Relations Consultant
Business Wire - Tue Dec 16, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV: ATE, OTCQX: ATBPF) today announced that they have, subject to approval by securities regulators, entered into an Investor Relations Consulting Agreement with Stonegate Capital Partners Inc. ("Stonegate" based in Dallas, Texas. Under the terms of the agreement Stonegate will receive a monthly fee of $4,000 for a minimum of 6 months and will be granted 24,000 options. Such options will vest quarterly starting on the date of the grant, will be exercisable at a price of $0.52, and will expire October 31, 2017. ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Reports Q2 2015 Interim Financial and Operating Results
Business Wire - Fri Nov 28, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV: ATE) filed its financial and operating results today for its fiscal quarter ended September 30, 2014. ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Provides Update on Its Acute Pain Drug ATB-352
Business Wire - Tue Nov 25, 6:30AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in the Company's pipeline, as described in the CEO Letter of April 2014. These studies have demonstrated that ATB-352 potently inhibits the production of pain-signalling chemicals (prostaglandins) in rats, but does not produce significant ulceration in the stomach or intestine, even at very high doses. In the same study, administration of the painkiller ketoprofen caused severe and extensive intestinal ulceration and bleeding. ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Completes Single Ascending Dose Portion of ATB-346 Phase I Program
Business Wire - Mon Oct 06, 6:30AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV:ATE; OTCQX:ATBPF) is pleased to report that the pre-scheduled single ascending dose portion of its Phase I program has been completed and has reached its primary objectives of safety and tolerability of ATB-346, up to the maximum dose tested (1500 mg). The results of this portion of the Phase I program have met the corporation's expectations based on extensive pre-clinical studies, and support the continuation of the Phase I program into the multiple ascending dose and food-effect portions, both of which are underway and are expected to be completed by January 2015. ATE.VN: 0.080 (+0.005)
Antibe Therapeutics Reports on Results of AGM Voting
Business Wire - Fri Oct 03, 6:30AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV:ATE; OTCQX:ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the Corporation held on October 1, 2014. ATE.VN: 0.080 (+0.005)
Merriman Capital Announces Sponsorship of Antibe Therapeutics Inc. on OTCQX
Thomson Reuters ONE - Mon Sep 15, 8:01AM CDT
SAN FRANCISCO - September 15, 2014 - Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it will serve as the Principal American Liaison (PAL) for Antibe Therapeutics Inc. (OTCQX: ATBPF) ("Antibe Therapeutics"
as it begins trading on OTCQX(R). The OTC announced today that the Antibe Therapeutics is now trading on the OTC market's highest tier, the OTCQX. Antibe Therapeutics Commences Trading on the US OTCQX Marketplace
Business Wire - Mon Sep 15, 6:30AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV: ATE, OTCQX: ATBPF) is pleased to announce that, as of today, common shares of the Corporation began trading in the United States on the OTCQX exchange under the ticker symbol "ATBPF". Antibe's common shares will continue to trade on the TSX Venture Exchange under the symbol "ATE". ATE.VN: 0.080 (+0.005)
OTC Markets Group Welcomes Antibe Therapeutics to OTCQX®
PR Newswire - Mon Sep 15, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Antibe Therapeutics Inc. (TSX-V: ATE; OTCQX: ATBPF), a human drug development company, has qualified to trade on OTCQX®, the best marketplace.
ATE.VN: 0.080 (+0.005)
Antibe Therapeutics' Founder Leads Study Identifying a Novel Mechanism for Treating Inflammatory Bowel Disease
Business Wire - Fri Sep 05, 6:30AM CDT
Antibe Therapeutics Inc.'s Founder and Chief Scientific Officer, Dr. John Wallace, is the senior author of an article published this week in the prestigious scientific journal Proceedings of the National Academy of Science USA describing research that may lead to a significant improvement in the treatment of Crohn's Disease and Ulcerative Colitis, collectively known as "inflammatory bowel disease" (IBD).
ATE.VN: 0.080 (+0.005)
